A new study found that semaglutide benefits extend beyond weight loss by easing osteoarthritis symptoms. Tatsiana Volkava/Getty Images
A new study reports that GLP-1 semaglutide medications may help reverse the effects of osteoarthritis in the joints.
Combining GLP-1 drugs with a healthy lifestyle may reduce cardiovascular risks in people with diabetes. Image Credit: Witthaya Prasongsin/Getty Images
A recent study found that people with type 2 diabetes who used GLP-1 receptor agonists (GLP-1 RAs) in combination with healthy lifestyle habits had a reduced risk of major adverse cardiovascular events.
Reports of people developing scurvy while taking GLP-1 medications are on the rise. Milles Team/Shutterstock
Reports of GLP-1 users developing scurvy have increased in recent months.
GLP-1 drugs can lead to malnutrition since they reduce appetite and food consumption.
Researchers believe that high doses of semaglutide may reduce blood flow to the optic nerve, which could lead to eye stroke. Maria Korneeva/Getty Images
A new study has found that the GLP-1 drug Wegovy is linked with a higher risk of “eye stroke,” especially in men.
Ischemic optic neuropathy (ION) is a rare but serious condition that can cause vision loss or even blindness.
A small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections. Image Credit: Siluk/UCG/Universal Images Group via Getty Images
A recent small study found that reduced GLP-1 frequency may help people maintain their weight loss.
Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy to treat pre-existing diabetes. However, a large study of over 750,000 pregnancies found that there was no link to preterm births or other obstetric complications if the medication was being used to lose weight. The authors of the study, published in Human Reproduction Open, say their findings suggest that it is diabetes rather than the drugs that may be contributing to the increased risk of preterm births.
The GLP-1 fight has moved from injectables to pills, and Structure Therapeutics Inc. is in the ring with phase III-ready aleniglipron. According to the Bay Area biotech, its oral once-daily glucagon-like peptide-1 (GLP-1) drug candidate, aleniglipron, demonstrated an absolute weight loss of “up to 39 pounds” in the 44-week Access II trial.
Rules determining who gets access to semaglutide in India were written for different bodies with different cardiovascular risks.
(MedPage Today) -- For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their arrhythmia, observational data suggested.
People who came out of catheter ablation...
(MedPage Today) -- Patients on GLP-1 or GLP-1/GIP agonists had significant residual gastric volume (RGV) if the medication wasn't held prior to upper endoscopy unless they were on a clear liquid diet the day before, the OCULUS randomized trial...